Check Cap (MBAI) Hisse Fiyat

Check Cap Fiyat

NASDAQ·KAPALI
3,11
​
Pazar kapalı

Check Cap hisse senedi fiyatı

Bu verilere Eulerpool API üzerinden ulaşın

Check Cap iş modeli ve hisse analizi

Check Cap Ltd, erken evre kolon kanseri tespiti için invaziv olmayan tanı teknolojilerinin geliştirilmesine uzmanlaşmış uluslararası bir biyoteknoloji şirketidir. Şirketin merkezi İsrail'de olup 2004 yılında kurulmuştur.

Check Cap hakkında sık sorulan sorular

The business model of Check Cap Ltd is focused on developing and commercializing an ingestible capsule system for colorectal cancer screenings. This innovative technology, known as the C-Scan, utilizes ultra-low dose X-ray technology to generate 3D images of the colon. By providing a non-invasive and patient-friendly alternative to traditional colonoscopies, Check Cap aims to increase the accessibility and early detection of colorectal cancer. This approach holds great potential in improving global healthcare outcomes and reducing healthcare costs associated with colorectal cancer screenings. As a leader in medical imaging technology, Check Cap Ltd is committed to driving advancements in the field of gastroenterology and revolutionizing cancer diagnostics.

Check Cap Ltd is primarily active in the healthcare industry, specifically in the field of medical diagnostics.

The main competitors of Check Cap Ltd in the market include companies such as Exact Sciences Corporation, Cerner Corporation, and Medtronic plc.

Check Cap Ltd is a pioneering medical technology company founded in 2004. The company focuses on the development of innovative capsule-based solutions for the medical imaging industry. Check Cap Ltd specializes in developing the C-Scan® system, a patient-friendly device designed to detect colorectal polyps and other gastrointestinal abnormalities. With cutting-edge imaging technology and a commitment to improving patient care, Check Cap Ltd has become a leading player in the medical imaging industry. Known for its dedication to innovation and its focus on improving diagnostic procedures, Check Cap Ltd continues to make significant advancements in the field of gastrointestinal imaging.

Check Cap Ltd has achieved several significant milestones in its journey. Some notable achievements include the successful completion of clinical trials for its C-Scan system, which is a revolutionary ingestible capsule for colorectal cancer screening. The company has also obtained CE Mark approval for the C-Scan system, allowing it to be marketed and sold in Europe. In addition, Check Cap Ltd has entered into partnerships and collaborations with renowned healthcare institutions and industry leaders, further enhancing its position in the market. These milestones highlight Check Cap Ltd's commitment to developing innovative solutions for early detection and prevention of colorectal cancer.

Check Cap Ltd is primarily present in Israel, the United States, and Europe.

Check Cap Ltd is committed to upholding strong values and a clear corporate philosophy. As a company specializing in medical diagnostics, Check Cap prioritizes integrity, innovation, and excellence in its operations. By developing cutting-edge technologies, Check Cap aims to revolutionize the field of screening and early detection of colorectal cancer. The company's core philosophy revolves around patient care, providing non-invasive solutions for effective diagnosis. Check Cap Ltd strives to foster an environment of trust, transparency, and social responsibility, driving its commitment to improving healthcare outcomes and enhancing patients' lives.

6 analist şu anda Check Cap hissesini değerlendiriyor: 0 al, 3 tut, 3 sat öneriyor. 2026 için analistler Check Cap şirketinin 4,76 M USD gelir ve -0,16 USD hisse başına kâr üretmesini bekliyor.

Güncel döviz kuruyla Check Cap hissesi 2,78 EUR (3,11 USD) seviyesindedir.

Check Cap hissesi (MBAI) 3 borsada işlem görür, bunlar arasında: NASDAQ (CHEK), Frankfurt (7CC.F), München (7CC.MU).

Check Cap Ltd is a research-based medical technology company based in Israel. It develops products for the prevention, diagnosis, and monitoring of gastroenterological diseases, with its core product being the C-Scan®. The C-Scan® is a non-invasive, capsule-based technology that allows for the scanning of the entire digestive tract to detect potential tumors or other abnormalities early on. It offers an alternative to traditional colonoscopies and improves diagnostic accuracy. The C-Scan® is easy to use, painless, and requires no prior preparation or cleaning of the colon. Check Cap also conducts clinical studies to develop and test medications for gastroenterological diseases and works on new technologies for better visualization of the digestive tract. Its business model combines research and development, clinical studies, product development, and partnerships with other companies and institutions. With its innovative technology, Check Cap has the potential to change the way gastroenterological diseases are diagnosed, treated, and monitored.

beklenen'nin Check Cap hasılatı 4,76 M USD'dir. Bu rakam, mevcut finansal verilere dayanmakta ve şirketin iş performansını yansıtmaktadır.

beklenen'nin Check Cap karı -145.800,00 USD'dir. Net kar, tüm giderleri düştükten sonra şirketin kârlılığını gösterir.

Check Cap'nin Fiyat/Kazanç (F/K) oranı şu anda -18,99'dir. F/K oranı, cari hisse fiyatını hisse başına kazançla karşılaştırır ve yatırımcıların Check Cap hisse senedinin değerlemesini değerlendirmelerine yardımcı olur.

Check Cap'nin Fiyat/Satış (F/S) oranı şu anda 0,58'dir. F/S oranı, pazar kapitalizasyonunu yıllık gelirle karşılaştırır ve Check Cap hisse senedinin değerleme metriği olarak hizmet eder.

Check Cap'nin Eulerpool Kalite Puanı 2/10'dur.

Check Cap'nin ISIN'i IL0011336851'dir. ISIN (Uluslararası Menkul Kıymetler Kimlik Numarası), menkul kıymetler için küresel olarak benzersiz bir tanımlayıcıdır.

Check Cap'nin WKN'i A14QUF'dir. WKN (Wertpapierkennnummer), menkul kıymetleri tanımlamak için kullanılan altı haneli bir Alman kimlik numarasıdır.

Check Cap'nin ticker'ı MBAI'dir. Ticker sembolü, Check Cap hisseleri borsada işlem görmek için kullanılır.

Adil DeğerTerminal
2,89 USD
Aşırı-/Eksik DeğerlemeTerminal
Adil Değerlenmiş
Sektor
Sektör
Sağlık Hizmetleri Ekipmanları & Malzemeleri
Hisse Sayısı
Çalışan Sayısı
Gelir Büyümesi Ø5 Yıl
EBIT Büyümesi Ø5 Yıl
Net Kar Büyümesi Ø5 Yıl
Web Sitesi check-cap.com
Ülke
İsrail
Para Birimi
USD
Halka Arz
19 Şub 2015
ISIN
IL0011336851
CUSIP
M2361E203
SEDOL
BVTGHG0
Pazar Kapitalizasyonu
22,67 M USDMicro Cap
52 Haftalık Aralık
AAQS
3 / 10
PEG
—
P/E
F/K Oranı 2026
-18,99
F/K Oranı 2027
—
P/S
F/S Oranı
0,58
EV/EBIT
—
KBV
6,60
ROIC
119,90 %
Son güncelleme 10 Eki 2026 17:15

Check Cap Emsaller Grubu

Check Cap Ticker

FRANKFURT · 7CC.FMÜNIH · 7CC.MUNASDAQ · CHEK

Check Cap FIGI

CHEK:US · BBG0089RJVS4CHEK:UA · BBG0089RJVT3CHEK:UC · BBG0089RJVV0CHEK:UN · BBG0089RJVX8CHEK:UP · BBG0089RJVY7CHEK:UB · BBG0089RJW02CHEK:UM · BBG0089RJW20CHEK:UX · BBG0089RJW39CHEK:UR · BBG0089RJW48CHEK:UD · BBG0089RJW93CHEK:UF · BBG0089RJWD8CHEK:VY · BBG0089RJWF6

Check Cap'nin tüm temel göstergeleri ve derinlemesine analizi

Check Cap hissesine yönelik aktienanalizimiz, satış, kar, P/E oranı, P/S oranı, EBIT gibi önemli mali kriterleri içermekte olup, dividende bilgilerini de ele almaktadır. Ayrıca, hisseler, piyasa değeri, borçlar, özsermaye ve Check Cap şirketin yükümlülükleri gibi konuları incelemekteyiz. Bu konular hakkında daha detaylı bilgilere ihtiyacınız varsa, web sitemizin alt sayfalarında kapsamlı analizler sunuyoruz: